Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 21, which means every article in Clinical Investigation has got 21 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

  2020 2019 2018 2017 2016

Year wise published articles

28 19 22 19 2

Year wise citations received

222 233 233 230 181
Journal total citations count 1936
Journal impact factor 6.44
Journal 5 years impact factor 12.56
Journal cite score 10.78
Journal h-index 21
Journal h-index since 2016 18
Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/
{Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3
  • Helms PJ, Dicks P (2013) The Scottish Children's Research Network: challenges, opportunities and achievements. Clinical Investigation 3: 433-439.

    View at Publisher | View at Google Scholar
  • Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?. Diabetes. 2012 Sep 1;61(9):2199-204. View at Publisher | View at Google Scholar | View at Indexing
  • Wright EM. Glucose transport families SLC5 and SLC50. Molecular aspects of medicine. 2013 Jun 30;34(2):183-96. View at Publisher | View at Google Scholar | View at Indexing
  • Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ (2012) Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Advances in therapy. 1:1-1.

    View at Publisher | View at Google Scholar
  • Misra M (2013) SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology 65(3):317-27. View at Publisher | View at Google Scholar | View at Indexing
  • Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC et al. (2013) Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. International journal of clinical pharmacology and therapeutics (2):132-40.

    View at Publisher | View at Google Scholar
  • Kanwal A, Banerjee SK (2013) SGLT inhibitors: a novel target for diabetes. Pharmaceutical patent analyst (1):77-91. View at Publisher | View at Google Scholar | View at Indexing
  • Yamaguchi K, Kato M, Suzuki M, Hagita H, Takada M, Ayabe M, Aso Y, Ishigai M, Ikeda S. In vitro–in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. Journal of Pharmacology and Experimental Therapeutics. 2013 Apr 1;345(1):52-61. View at Publisher | View at Google Scholar | View at Indexing
  • Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes research and clinical practice. 2014 Sep 30;105(3):313-21. View at Publisher | View at Google Scholar | View at Indexing
  • 王小彦, 王玉丽, 徐为人. 近几年治疗糖尿病热点靶点的研究进展. 药物评价研究. 2012 Feb. View at Publisher | View at Google Scholar | View at Indexing
  • Yamaguchi K, Kato M, Ozawa K, Kawai T, Yata T et al. (2012) Pharmacokinetic and pharmacodynamic modeling for the effect of sodium–glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. Journal of pharmaceutical sciences 101(11):4347-56. View at Publisher | View at Google Scholar | View at Indexing
  • Deshmukh AB, Patel MC, Mishra B (2013) SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus. Renal failure 35(4):566-72. View at Publisher | View at Google Scholar | View at Indexing
  • Malla P, Kumar R, Mahapatra MK, Kumar M (2014) Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure. Medicinal research reviews 34(6):1146-67. View at Publisher | View at Google Scholar | View at Indexing
  • Liu J, Lee T (2011) 7 SGLT2 Inhibitors for Type 2 Diabetes. Annual Reports in Medicinal Chemistry. 46:103 View at Publisher | View at Google Scholar | View at Indexing
  • Cersosimo E, Solis-Herrera C, Triplitt C (2014) Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. Jornal Brasileiro de Nefrologia 36(1):80-92. View at Publisher | View at Google Scholar | View at Indexing
  • Urba WJ, Curti BD (2012) Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches. Clinical Investigation 2: 957-959.

    View at Publisher | View at Google Scholar
  • Urba WJ, Curti BD (2012) advances in immunotherapy and targeted approaches. Clin Invest 2: 957–959.

    View at Publisher | View at Google Scholar
  • 王小彦, 王玉丽, 陈娇, 赵桂龙, 徐为人, 汤立达. 新型糖苷类衍生物降糖作用筛选和研究. 中草药. 2013 Feb;4:454458. View at Publisher | View at Google Scholar | View at Indexing
  • 王玉丽, 王小彦, 赵桂龙, 邵华, 徐为人, 汤立达. é’ -葡萄糖协同转运蛋白 2 抑制剂类抗糖尿病新药的研发概况. 现代药物与临床. 2012;2:015. View at Publisher | View at Google Scholar | View at Indexing
  • 任安. 新型抗糖尿病药物研究进展. 安徽医学. 2014(10):1341-3.

    View at Publisher | View at Google Scholar
  • Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C (2015) Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer. Clinical lung cancer 16: 86-91.

    View at Publisher | View at Google Scholar
  • Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, et al. (2015) ( The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient–derived xenograft models. Clinical Cancer Research 21: 2811-2819.

    View at Publisher | View at Google Scholar
  • Wang ZX, Sun J, Howell CE, Zhou QY, He ZX, et al. (2014) Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental & clinical pharmacology 28: 551-582.

    View at Publisher | View at Google Scholar
  • Hamilton G, Rath B, Burghuber O (2015)Pharmacokinetics of crizotinib in NSCLC patients. Expert opinion on drug metabolism & toxicology 11: 835-842.

    View at Publisher | View at Google Scholar
  • 吕昕泽, 孙波, 杨微, 于飞, 傅晟. 治疗 2 型糖尿病新药 ipragliflozin. 中国新药杂志. 2015;24(3):241-4. View at Publisher | View at Google Scholar | View at Indexing
  • Schrödl K, Von Schilling C, Tufman A, Huber RM, Gamarra F (2014) Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. Respiration 88: 262-264.

    View at Publisher | View at Google Scholar
  • Zhang Y, Jain RK, Zhu M (2015) Recent progress and advances in HGF/MET-targeted therapeutic agents for cancer treatment. Biomedicines 3: 149-181.

    View at Publisher | View at Google Scholar
  • Vrhovac I, Breljak D, Karaica D, Radović N, Jadrijević S et al. HOĆE LI INHIBITORI PRIJENOSA GLUKOZE U TERAPIJI DIJABETESA DJELOVATI SPECIFIÄŒNO U BUBREZIMA?. View at Publisher | View at Google Scholar | View at Indexing
  • Kurata Y, Miyauchi N, Suno M, Ito T, Sendo T, et al. (2015) Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. Journal of pharmaceutical health care and sciences 1: 8.

    View at Publisher | View at Google Scholar
  • 曾要富, 姚亮元, 钟爱军, 朱颖熹, 袁秀菊. SGLT2 抑制剂 Canagliflozin——â…¡ 型糖尿病治疗的新药. 中国现代应用药学. 2014;31(9):1154-60. View at Publisher | View at Google Scholar | View at Indexing
  • Riessk J (2013) Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape. The American journal of managed care 19: s390-s397.

    View at Publisher | View at Google Scholar
  • 徐红燕, 杜有功, 陈赛贞. é’ -葡萄糖协同转运体 2 抑制剂的研究进展. 中国医院用药评价与分析. 2014(6):489-92. View at Publisher | View at Google Scholar | View at Indexing
  • Pinho JR, Sitnik R, Mangueira CL (2014) Personalized medicine and the clinical laboratory. Einstein (São Paulo) 12: 366-373.

    View at Publisher | View at Google Scholar
  • Geeleher P, Gamazon ER, Seoighe C, Cox NJ, Huang RS (2016) Consistency in large pharmacogenomic studies. Nature Dec 540: E1-E2.

    View at Publisher | View at Google Scholar
  • 黎克江. 治疗糖尿病的热点靶点的研究近况. 中国卫生产业. 2013;10(33):19-20.

    View at Publisher | View at Google Scholar
  • 田培超, 刘玉峰, 王怀立, 罗强, 陈铮, 王越 (2014) 间变性淋巴瘤激酶抑制剂对人神经母细胞瘤细胞凋亡的影响. 中华实验外科杂志. 31: 2006-2008.

    View at Publisher | View at Google Scholar
  • Schwaederle M, Zhao M, Lee JJ (2016) Supplementary Online Content.

    View at Publisher | View at Google Scholar
  • Cass Y, Connor TH, Tabachnik A (2016) Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. Journal of Oncology Pharmacy Practice. 2016 Mar 22:1078155216637217.

    View at Publisher | View at Google Scholar
  • Piccolo KM, Boullata JI (2015) The Influence of Polypharmacy on Nutrition. InPreventive Nutrition 83-113.

    View at Publisher | View at Google Scholar
  • Nehoff H (2016) The use of combination tyrosine kinase inhibitors for the treatment of glioblastoma multiforme (Doctoral dissertation, University of Otago).

    View at Publisher | View at Google Scholar
  • 劉岡易 (2016) 臺灣晚期 ALK 基因變異陽性非小細胞肺癌患者使用 Crizotinib 作為第一線藥物之成本效用分析. 臺灣大學健康政策與管理研究所學位論文 1: 1-20.

    View at Publisher | View at Google Scholar
  • Rebello Pinho JR, Sitnik R, Pitangueira Mangueira CL (2014) Medicina personalizada e o laboratório clínico. Einstein (16794508) 12.

    View at Publisher | View at Google Scholar
  • Reitamo S, Remitz A. Topical agents for atopic dermatitis.

    View at Publisher | View at Google Scholar
  • Pinho JR, Sitnik R, Mangueira CL (2014) Medicina personalizada e o laboratorio clinico. Medicine Mates 12.

    View at Publisher | View at Google Scholar
  • 张妍, 石远凯, 韩晓红 (2014) 肿瘤药物基因组学研究进展. 中国新药杂志 23: 1999-2003.

    View at Publisher | View at Google Scholar
  • Zhou H, Ji X, Wu Y, Xuan J, Qi Z, et al. (2014) A dual-role of Gu-4 in suppressing HMGB1 secretion and blocking HMGB1 pro-inflammatory activity during inflammation. PLoS one. 9(3):e89634. View at Publisher | View at Google Scholar | View at Indexing
  • Wu QY, Sun MR, Wu CL, Li Y, Du JJ, et al. Activation of calcium-sensing receptor increases TRPC3/6 expression in T lymphocyte in sepsis. Molecular immunology 64(1):18-25. View at Publisher | View at Google Scholar | View at Indexing
  • 李志军, 任新生, 李银平. " 三证三法" 及" 菌毒炎并治" 治疗脓毒症的研究进展 [J]. 中国中西医结合外科杂志. 2012 Jul 6;18(6):553-.

    View at Publisher | View at Google Scholar
  • 彭志允, 彭环庆, 林辉文, 唐钟祥, 李烽辉, 王颖菁. 补气养阴活血法治疗脓毒症患者急性肾损伤的临床观察. 辽宁中医杂志. 2015;42(2):326-8. View at Publisher | View at Google Scholar | View at Indexing
  • Coleman K (2011) Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Current opinion in microbiology 14(5):550-5. View at Publisher | View at Google Scholar | View at Indexing

Relevant Topics